Cardinal Health (NYSE:CAH) Releases Quarterly Earnings Results, Beats Expectations By $0.26 EPS

Cardinal Health (NYSE:CAH) issued its earnings results on Friday. The company reported $1.88 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.62 by $0.26, Briefing.com reports. The company had revenue of $52.28 billion for the quarter, compared to analysts’ expectations of $50.90 billion. Cardinal Health had a negative return on equity of 56.56% and a net margin of 0.56%. Cardinal Health’s quarterly revenue was down 4.3% compared to the same quarter last year. During the same period last year, the business earned $1.73 EPS. Cardinal Health updated its FY25 guidance to $7.75-7.90 EPS and its FY 2025 guidance to 7.750-7.900 EPS.

Cardinal Health Stock Down 3.6 %

Shares of CAH opened at $111.90 on Tuesday. The business’s 50-day moving average price is $111.75 and its 200-day moving average price is $104.15. Cardinal Health has a twelve month low of $93.17 and a twelve month high of $119.13. The stock has a market cap of $27.08 billion, a PE ratio of 21.77, a P/E/G ratio of 1.57 and a beta of 0.60.

Cardinal Health Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, October 15th. Stockholders of record on Tuesday, October 1st were given a $0.506 dividend. The ex-dividend date was Tuesday, October 1st. This is a boost from Cardinal Health’s previous quarterly dividend of $0.51. This represents a $2.02 annualized dividend and a dividend yield of 1.81%. Cardinal Health’s payout ratio is 39.30%.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on CAH. StockNews.com lowered shares of Cardinal Health from a “strong-buy” rating to a “buy” rating in a research note on Sunday. Robert W. Baird lifted their price target on Cardinal Health from $130.00 to $137.00 and gave the company an “outperform” rating in a research note on Thursday, August 15th. Evercore ISI raised their target price on Cardinal Health from $105.00 to $115.00 and gave the company an “in-line” rating in a report on Thursday, August 15th. Citigroup cut their target price on Cardinal Health from $115.00 to $107.00 and set a “neutral” rating on the stock in a research report on Friday, July 19th. Finally, Barclays increased their price target on Cardinal Health from $117.00 to $133.00 and gave the company an “overweight” rating in a research report on Monday. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, Cardinal Health has an average rating of “Moderate Buy” and an average target price of $123.00.

Insider Activity at Cardinal Health

In other news, CEO Jason M. Hollar sold 26,716 shares of the business’s stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $108.87, for a total transaction of $2,908,570.92. Following the completion of the transaction, the chief executive officer now owns 244,091 shares of the company’s stock, valued at approximately $26,574,187.17. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Cardinal Health news, CEO Jason M. Hollar sold 26,716 shares of the firm’s stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $108.87, for a total transaction of $2,908,570.92. Following the sale, the chief executive officer now owns 244,091 shares in the company, valued at $26,574,187.17. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Jessica L. Mayer sold 17,896 shares of the business’s stock in a transaction that occurred on Thursday, August 15th. The stock was sold at an average price of $106.48, for a total value of $1,905,566.08. Following the completion of the sale, the insider now owns 94,529 shares of the company’s stock, valued at $10,065,447.92. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 113,963 shares of company stock valued at $12,379,980. Corporate insiders own 0.09% of the company’s stock.

Cardinal Health Company Profile

Cardinal Health, Inc operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home.